Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS"
- PMID: 33182499
- PMCID: PMC7665122
- DOI: 10.3390/ijms21218411
Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS"
Abstract
Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by arterial and/or venous thrombosis and/or pregnancy morbidity, associated with circulating antiphospholipid antibodies (aPL). In some cases, patients with a clinical profile indicative of APS (thrombosis, recurrent miscarriages or fetal loss), who are persistently negative for conventional laboratory diagnostic criteria, are classified as "seronegative" APS patients (SN-APS). Several findings suggest that aPL, which target phospholipids and/or phospholipid binding proteins, mainly β-glycoprotein I (β-GPI), may contribute to thrombotic diathesis by interfering with hemostasis. Despite the strong association between aPL and thrombosis, the exact pathogenic mechanisms underlying thrombotic events and pregnancy morbidity in APS have not yet been fully elucidated and multiple mechanisms may be involved. Furthermore, in many SN-APS patients, it is possible to demonstrate the presence of unconventional aPL ("non-criteria" aPL) or to detect aPL with alternative laboratory methods. These findings allowed the scientists to study the pathogenic mechanism of SN-APS. This review is focused on the evidence showing that these antibodies may play a functional role in the signal transduction pathway(s) leading to thrombosis and pregnancy morbidity in SN-APS. A better comprehension of the molecular mechanisms triggered by aPL may drive development of potential therapeutic strategies in APS patients.
Keywords: PTMs; SN-APS; TLR-4 pathways; lipid rafts; β2GPI; “non-criteria” aPL.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements.Clin Rheumatol. 2019 Feb;38(2):371-378. doi: 10.1007/s10067-018-4251-7. Epub 2018 Aug 11. Clin Rheumatol. 2019. PMID: 30099654
-
The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study.Arthritis Res Ther. 2022 Jan 3;24(1):9. doi: 10.1186/s13075-021-02702-9. Arthritis Res Ther. 2022. PMID: 34980238 Free PMC article.
-
The role of TLR4 in pathophysiology of antiphospholipid syndrome-associated thrombosis and pregnancy morbidity.Br J Haematol. 2014 Jan;164(2):165-76. doi: 10.1111/bjh.12587. Epub 2013 Oct 8. Br J Haematol. 2014. PMID: 24180619 Review.
-
Antiphospholipid syndrome, "the best prophet of the future".Mod Rheumatol. 2018 May;28(3):409-416. doi: 10.1080/14397595.2018.1435988. Epub 2018 Feb 21. Mod Rheumatol. 2018. PMID: 29385876 Review.
-
Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management.Haematologica. 2020 Mar;105(3):562-572. doi: 10.3324/haematol.2019.221945. Epub 2020 Jan 30. Haematologica. 2020. PMID: 32001534 Free PMC article. Review.
Cited by
-
Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive Patients.Biomedicines. 2023 Dec 16;11(12):3329. doi: 10.3390/biomedicines11123329. Biomedicines. 2023. PMID: 38137550 Free PMC article.
-
Anti-β2GPI/β2GPI complex promotes thrombosis by activating the P2Y2/MAPKs pathway to increase human neutrophil peptides.PLoS One. 2025 May 22;20(5):e0322447. doi: 10.1371/journal.pone.0322447. eCollection 2025. PLoS One. 2025. PMID: 40403008 Free PMC article.
-
Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.Front Immunol. 2022 Sep 27;13:978910. doi: 10.3389/fimmu.2022.978910. eCollection 2022. Front Immunol. 2022. PMID: 36238309 Free PMC article.
-
Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke.Front Cardiovasc Med. 2021 May 3;8:665741. doi: 10.3389/fcvm.2021.665741. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34012984 Free PMC article.
-
Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation.Front Immunol. 2023 Mar 2;14:1129201. doi: 10.3389/fimmu.2023.1129201. eCollection 2023. Front Immunol. 2023. PMID: 36936925 Free PMC article.
References
-
- Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H.W.M., Groot P.G.D.E., Koike T., Meroni P.L., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J. Thromb. Haemost. 2006;4:295–306. doi: 10.1111/j.1538-7836.2006.01753.x. - DOI - PubMed
-
- Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., Jacobsen S., Lakos G., Tincani A., Kontopoulou-Griva I., et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 2002;46:1019–1027. doi: 10.1002/art.10187. - DOI - PubMed
-
- Yelnik C.M., Urbanski G., Drumez E., Sobanski V., Maillard H., Lanteri A., Morell-Dubois S., Caron C., Dubucquoi S., Launay D., et al. Persistent triple antiphospho lipid antibody positivity as a strong risk factor of frst thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2017;26:163–169. doi: 10.1177/0961203316657433. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous